Skip to main content

Drug Interactions between cinacalcet and denosumab

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

cinacalcet denosumab

Applies to: cinacalcet and denosumab

MONITOR: Coadministration of denosumab with calcimimetic drugs such as cinacalcet and etelcalcetide, may increase the risk of hypocalcemia. This risk may be significantly higher in patients with severe renal dysfunction (creatinine clearance less than 30 mL/min) and in those receiving dialysis. The mechanism of this interaction is thought to be due to additive hypocalcemic effects.

MANAGEMENT: Caution and close monitoring of serum calcium concentrations are recommended when denosumab is used concomitantly with calcimimetic drugs such as cinacalcet and etelcalcetide. Patients and clinicians should be alert for signs and symptoms of hypocalcemia, such as numbness or tingling in the fingers, toes, or around the mouth, muscle spasms, twitches or cramps, seizures, mental status changes (confusion, irritability, depression), and irregular heartbeats.

References (2)
  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2010) "Product Information. Prolia (denosumab)." Amgen USA

Drug and food interactions

Moderate

cinacalcet food

Applies to: cinacalcet

ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of cinacalcet. According to the product labeling for cinacalcet, administration with a high-fat meal increased the peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of cinacalcet by 82% and 68%, respectively, compared to administration in the fasting state. The Cmax and AUC were increased 65% and 50%, respectively, when cinacalcet was administered with a low-fat meal compared to fasting.

MANAGEMENT: To ensure maximal oral absorption, cinacalcet should be administered with or immediately after a meal. The tablets should be taken whole and not divided or crushed.

References (1)
  1. (2004) "Product Information. Sensipar (cinacalcet)." Amgen USA

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer